We found no difference in serum levels of YKL-40 values between AD patients and HCs, whereas plasma levels of YKL-40 values differed significantly between the two groups, which may provide part of the evidence for considering plasma levels of YKL-40 as a potential peripheral biomarker for AD. This evidence concerns the gene CHI3L1 and Alzheimer disease.